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Neuroprotection is the preservation of the structure and function of neurons from insults arising from cellular injuries induced
by a variety of agents or neurodegenerative diseases (NDs). The various NDs including Alzheimer’s, Parkinson’s, and Huntington’s
diseases as well as amyotropic lateral sclerosis affect millions of people around the world with the main risk factor being advancing
age. Each of these diseases affects specific neurons and/or regions in the brain and involves characteristic pathological andmolecular
features. Hence, several in vitro and in vivo study models specific to each disease have been employed to study NDs with the aim of
understanding their underlying mechanisms and identifying new therapeutic strategies. Of the most prevalent drug development
efforts employed in the past few decades, mechanisms implicated in the accumulation of protein-based deposits, oxidative stress,
neuroinflammation, and certain neurotransmitter deficits such as acetylcholine and dopamine have been scrutinized in great detail.
In this review, we presented classical examples of plant-derived neuroprotective agents by highlighting their structural class and
specific mechanisms of action. Many of these natural products that have shown therapeutic efficacies appear to be working through
the above-mentioned key multiple mechanisms of action.
1. Introduction
Neuroprotection is a term used to refer to strategies and
relative mechanisms that shield the central nervous sys-
tem (CNS) from neuronal injuries caused by chronic (e.g.,
Alzheimer’s and Parkinson’s diseases) or acute (e.g., stroke)
neurodegenerative diseases (NDs) [1].These acute or chronic
diseases result from breakdown and deterioration of neurons
of the CNS and often result in the deterioration of the
cognitive as well as the intellectual faculties of the sufferers.
The onset of NDs symptoms is usually gradual as well as
progressive and includes loss of memory, primarily short-
term, difficulty in learning, motor coordination, and many
other functional loses [2, 3]. Ageing, defined as a complex
physiological process involving both morphological and
biochemical changes that progressively unfold as we get
older [1], has been found to be closely associated with NDs.
Ageing stands out as a major risk factor among the other
etiological factors of NDs, including hypertension, genetic
and/or environmental factors, and infections. With increas-
ing age, aggregation of proteins, inflammation, oxidative
stress, and loss of neurotransmitters, which are common to
the pathology of NDs, also occur more often [1, 4, 5].
Nature remains to be a veritable source of medicines
to mankind. Many important drugs such as vincristine,
artemisinin, and gentamicin, which are still in use today, are
obtained from natural sources or are designed on structural
fingerprints of naturally occurring molecules [6, 7]. Further-
more, traditional medicine remains a vital alternative source
of medicine all over the world today with some estimate
suggesting to account to about 80% of the primary health
care system in some developing countries (e.g., Nigeria,
Ghana, China, and India [8, 9]). The increasing incidence
of resistance (especially to antibiotics and antimalarials),
undesirable side effects, high cost, and lack of efficacy after
prolonged usage of the existing drugs in use has led to a
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renewed interest in the development of new drug candidates
from natural sources [10, 11]. For example, drugs such as
amantadine, memantine, donepezil, selegiline, galantamine,
and rivastigmine that are clinically available for the manage-
ment of NDs are only able to provide symptomatic relief and
slow the progression of the diseases [12, 13]. These drugs,
such as the synthetic donepezil, are also associated with side
effects [14]. Hence, a great deal of research focus has been
given in recent years to herbs and other natural products
used in ethnomedicine around the world for age-related CNS
diseases.
Numerous natural products, but primarily plants extracts,
have been reported to be used in traditional medicine for
neuroprotective, memory enhancing, and antiageing pur-
poses. Examples of such plants include Ginkgo biloba, Panax
ginseng, Curcuma longa, Bacopa monnieri, and Salvia offici-
nalis [1, 15]. These plants have been studied to confirm the
traditional claim with special attention given in understand-
ing the mechanism by which they elicit the neuroprotective
effects. This review is designed to give a brief description of a
number of neurodegenerative diseases, the most important
pathological events associated with the diseases, and an
overview of therapeutic options with some popular plant-
derived neuroprotective agents.
2. Overview of Neurodegenerative Diseases
Neurodegenerative disease is a term used to refer to various
conditions which occur as a result of neuronal cell death,
particularly, those of the CNS [16].This deterioration is often
associated with gradual onset of progressive symptoms, a
major symptom being loss of memory. The NDs include
Alzheimer’s disease (AD), Parkinson’s disease (PD), Lewy
body dementia, multiple sclerosis, amyotrophic lateral scle-
rosis (ALS), and spongiform encephalopathy [13]. Of these
NDs, AD is the most prevalent, accounting for over 60–70%
of all forms of dementia [17]. Protein aggregation, inflamma-
tion, excitotoxicity, oxidative stress, and neurotoxicity have
been implicated in the pathophysiology of NDs [3].
2.1. Alzheimer’s Disease. The AD is the most prevalent and
devastating disorder of the NDs. It is an incurable disease
of cognition and behavioral impairment that affects social
and occupational activities and is also a leading cause of
institutionalization in the elderly [1, 18]. Clinically, AD
is characterized by a progressive and irreversible memory
deficits, cognitive deterioration, and personality changes,
with a mean duration of about 8.5 years between onset
of clinical symptoms and death [17]. Memory impairments
are first to appear in the early stage of the disease, after
whichmotor and sensory functions are affected as the disease
progresses. The onset of AD is usually above 65 years of age,
with risk from this age doubling every 5 years. Hence, it
has been suggested that the risk for AD for persons living
into their eighties rises to 20–40% depending on a variety
of factors such as population dynamics and geography [19].
As the world population continues to age in parallel with
economic development, the number of people with NDs and
the associated dementia also continues to increase [20]. This
increase has in turn prompted an enormous increment in
research interest and efforts on the discovery of new thera-
peutic agents for primary, auxiliary, or tertiary prevention of
these diseases [21].
The pathological hallmark of AD is the accumulation
of protein aggregates to form two major lesions, namely,
neurofibrillary tangles (NFTs) and senile plaques. Senile
plaques are composed of fibrillar amyloid 𝛽 (A𝛽) peptides
produced by cleavage of the A𝛽 precursor protein (APP),
whereas NFTs consist of hyperphosphorylated microtubule-
associated tau protein [22]. The mechanisms by which A𝛽
peptide aggregates act to cause AD are thought to include
induction of oxidative damage [23] as well as inflamma-
tion [24] and neurotoxicity [19]. It is now known that the
dysfunction of the central cholinergic system which plays
a key role in the retrieval and storage of memory in the
CNS is responsible for the cognitive deficit associated with
AD [25–27]. Reports of substantial neocortical deficits in
choline acetyltransferase (ChAT), the enzyme responsible for
the synthesis of acetylcholine (ACh), discoveries of reduced
choline uptake, ACh release, and loss of cholinergic perikarya
from the nucleus basalis ofMeynert, along with the emerging
roles of ACh in learning and memory, led to the “cholinergic
hypothesis of AD” [17].
2.2. Parkinson’s Disease. The PD is the second most common
ageing-related neurodegenerative diseases that can greatly
impair quality of life with significant consequences in terms
of cost of patient care [28]. Primarily amovement disorder, as
opposed toADwhich ismainly a cognitive disease, PD affects
approximately 1% of the human population over the age of 60
[4]. Its classical signs include resting tremors, bradykinesia,
extrapyramidal rigidity, and loss of postural reflexes such
as disturbance in walking or equilibrium. The PD involves
loss of dopaminergic neurons of the pars compacta region
of the substantia nigra and their terminals in the corpus
striatum [29]. Since neurodegeneration is not restricted to the
basal ganglia, PD is also linked with nonmotor disorder like
dementia.The association between PD and oxidative damage
of neuronal cells has been well established. For example, the
breakdown of dopamine (DA) by autooxidation has been
shown to be linked to semiquinone metabolism and the
generation of superoxide anion, hydrogen peroxide (H2O2),
and monoamine oxidase (MAO) expression [19].
2.3. Other Neurodegenerative Diseases. Amyotrophic lateral
sclerosis is thought to be caused by the mutation of the gene
coding for the enzyme superoxide dismutase (SOD) and also
by the misfolding of the same enzyme. The ALS is incurable
and has generally a median survival of three years from onset
to death. Its symptoms include tripping or stumbling when
running, foot and wrist drop, slurred speech, and depression
[30, 31]. Huntington disease (HD) is another incurable ND.
It has an adult onset with autosomal dominant inherited
disorder characterized by progressive brain degeneration,
causing rapid deterioration and eventually death. Symptoms
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of the diseases include involuntarymovement, dementia, and
behavioral changes [32].
Prion diseases refer to a group of rare NDs caused by
the aggregation of misfolded prion proteins. Prion proteins
are known to be infectious and are presumed to cause some
type of NDs referred to as spongiform encephalopathy: for
example, Creutzfeldt-Jacob disease and kuru in humans,
Scrapie in sheep, and bovine spongiform encephalopathy in
pigs collectively referred to as prion diseases. A major feature
of these diseases is that they are transmissible [33, 34].
Cerebrovascular diseases such as stroke cause acute
degeneration of the CNS unlike the previously discussed
chronic NDs. About 85% of stroke cases are of ischemic
origin and have a slightly different etiology from the chronic
ND. Interruption of blood supplies to the brain leads to a
cascade of events that causes irreversible neuronal damage.
Stroke is said to be the second leading cause of death in
industrialized countries [35] and has been reported to lead to
dementia in 25%of patientswithin threemonths after a stroke
[36]. Interestingly, the deposition of both A𝛽 and APP in the
cortical and subcortical brain areas of nondementia patients
following stroke has been reported [37].
3. Ageing
Ageing has been defined as a complex physiological process
involving both morphological and biochemical changes that
occur progressively [1]. These changes include those of the
CNS, the skin, the cardiovascular system, and hormonal
and reproductive systems. Ageing remains to be the leading
risk factor for NDs except for the familial forms which
are found to affect individuals younger than 60 [1, 4, 5].
Human life expectancy has increased rapidly over the past
decades especially in developed countries, and as the world
populations get older, age-related NDs such as AD and PD
have become more common [4, 38].
Although neuronal cell death is not programmed to
occur at a particular age, cellular and molecular changes that
occur with ageing interact with genes and environmental
factors to determine which cells age successfully and which
will suffer neurodegeneration [5]. Ageing is associated with
mitochondrial dysfunction, increased free radical produc-
tion and oxidative stress, microglia dysfunction, reduced
efficiency of chaperones, reduced synaptic densities, blood-
brain barrier disruption, and low levels of neurogenesis [5,
39, 40]. The accumulation of deletions of mitochondrial
DNA in ageing alongside functional impairment of neurons
results in age-related genetic changes in the substantia nigra
[41]. The oxidative neuronal damage in the ageing brain
is also associated with the decline in the production and
function of antioxidant enzymes [41]. Oxidative damage to
the mitochondrial DNA is believed to be caused by free
radicals of mitochondrial origin. Furthermore, ageing comes
with an alteration in the composition of the cell membrane
fatty acids. The polyunsaturated fatty acids (PUFAs), like
arachidonic acids, are abundant in ageing brain and are
highly susceptible to oxidative damage like lipid peroxida-
tion. Histopathological changes also occur with microglia
morphology and activity during neuroinflammation in the
aged brain. Moreover, aged microglia have shorter and
less motile processes and larger soma sizes compared with
microglia in younger animals [42]. Also, phagocytosis func-
tion of the microglia appears to be altered in the aged brain
[43], and aged microglia exhibit increased expression of the
phagosomal/lysosomal associated marker. There is increased
levels of proinflammatory cytokines such as interleukin-6
(IL-6), IL-1𝛽, and tumour necrosis factor (TNF), as well as
altered levels of the anti-inflammatory cytokines such as IL-
10 and transforming growth factor (TGF) 𝛽1 [39].
Progressive accumulation of iron in the brain and sub-
stantia nigra with age renders neuronal cells more susceptible
to toxins [44]. The sirtuins, members of the histone deacety-
lase family of proteins, are also vital for cellular functions
and play a role in ageing. Inhibition of sirtuin 2 (SIRT2)
has been shown to rescue the toxicity of 𝛼-synuclein and
modified inclusion morphology in animal models of PD,
indicating a link between ageing and neurodegeneration [45].
The activity of proteasome, whose function is linked to the
degradation of damaged or ubiquitinated proteins, is also
known to be reduced with ageing. Consequently, an increase
in abnormal deposition of cellular brain proteins continues
with the ageing process [46]. The insulin/insulin-like growth
factor 1 (IGF1) signaling pathway that serves as a lifespan,
metabolism, and stress-resistance regulator has been found
to be associated with neurodegeneration during the ageing
process. As the optimal functioning of this pathway is key
to maximizing longevity, a reduction of insulin signaling
results in diabetes, reduced longevity, and prevalent protein
aggregation-mediated toxicity [47]. There is also increasing
evidence to suggest that cognitive dysfunction due to loss or
decline of the cholinergic activity in the key areas of the brain
is a normal biological process associatedwith ageing aswell as
some forms of progressive neurodegenerative disorders such
as AD [48].
4. Common Pathophysiological Hallmark of
Neuronal Cell Death
4.1. ProteinMisfolding and Aggregation. For proteins to prop-
erly function in the biological system, they must maintain
their three-dimensional conformation.The process by which
polypeptide chains fold into this three-dimensional structure
is termed protein folding. The correct three-dimensional
structure, which is dependent on the sequence of amino
acids, is very essential in the proper functioning of the
protein. This intricate stepwise process can however go
wrong leading to the adoption of abnormal configuration
by the protein, a process called protein misfolding. Mis-
folded proteins lose their natural activity and in several
cases become deleterious and are unable to return to their
native conformation. These proteins expose hydrophobic
terminals that are supposed to be buried in their core leading
to the formation of insoluble aggregates. Since misfolded
conformation can be generated spontaneously at low rate
throughout life, their aggregates gradually accumulate as we
age.These aggregates form distinct and observable structures
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in the brain which are generally known as amyloid deposits
in the brain. Furthermore, some form of mutation increases
the chance of misfolding in proteins which is the case in the
genetic or familial case of NDs [22].
Though the mechanism is not clear, it has been proven
that deposits of misfolded proteins are known to be neuro-
toxic and able to cause apoptosis in neuronal cells. There are
however mechanisms that are able to inhibit aggregation of
proteins and protect the CNS from such danger. Examples
of these include the chaperones that are able to bind to
misfolded protein and cause them to fold into their native
structure and also the “ubiquitination” reaction. However,
when these systems are unable to cope, aggregation takes
place and the subsequent neuronal cell death becomes
inevitable [46, 49].
As described in the preceding texts, two microscopic fea-
tures resulting from the misfolding of proteins are observed
in AD: extracellular amyloid plaques (senile plaque) con-
sisting of amorphous extracellular deposits of A𝛽 and the
NFTs of the hyperphosphorylated microtubule-associated
tau protein [1, 22]. Amyloid deposits consist of aggregates
containing 40 or 42 amino acid residues. Aggregates of 42
residue are more likely to form and are also overproduced
when there is a genetic mutation [22]. In rare cases of early
onset of PD which runs in some families, mutations in a
synaptic protein called 𝛼-synuclein that was originally iden-
tified from smaller peptides isolated in amyloid-containing
fractions of AD brains are observed [50, 51]. The 𝛼-synuclein
proteins are synaptic proteins that are able to aggregate and
form fibrils and are the major component of the Lewy body
lesions, characteristic of PD as well as certain cases of AD and
several other neurodegenerative conditions [52]. In the HD,
mutation of huntingtin, a cytoplasmic protein, leads to its
aggregation and forms inclusions in cell nucleus in the brain.
These aggregations, alongside the interaction of mutated
huntingtin protein with regulatory caspases, are believed to
be component of the pathophysiology of HD [53]. In the case
of ALS, it is the SOD that aggregates. There is evidence to
suggest that the accumulation of SOD aggregate may lead to
inflammation and neurotoxicity [54].
4.2. Oxidative Stress. Oxidative stress occurs when the
body’s antioxidant defense system can no longer cope with
the neutralization of free radicals and/or reactive oxygen
species (ROS) produced in the body. Free radicals have
incomplete electron shells making them more chemically
reactive than molecules with complete electron shells. They
are formed in the course of normal cellular respiration
and metabolism, especially under the influence of certain
environmental chemicals and sunlight. When an oxygen
molecule (O2) becomes electrically charged, it tries to steal
electrons from neighboring molecules, causing damage to
the DNA and other molecules. This damage may over time
become irreversible, thereby leading to damage of cells and
the body. The ROS are highly reactive molecules produced
in the course of oxygen metabolism in the mitochondrial
respiratory chain [55–59]. The term ROS when used implies
superoxide radicals (O2
∙−), hydroxyl radicals (∙OH), hydro-
gen peroxide (H2O2), and hydroperoxyl radicals (
∙HO2).
Other ROS include reactive sulphur species and the reactive
nitrogen species such as nitric oxide (NO) and peroxynitrite
(O=N–O–O−). The brain with only 2% of the body mass
but responsible for about 20% of the oxygen utilization is
particularly susceptible to oxidative damage [1, 59]. Fur-
thermore, the brain tissues are readily susceptible to lipid
peroxidation reactions due to the high amount of PUFAs
present in neuronal membranes. The result of this is the
formation of cytotoxic aldehydes, such as malondialdehyde
(MDA) and 4-hydroxynonenal [55–60]. Several studies have
shown that cellular damage arising from free radicals and/or
ROS is implicated in the etiology andpathophysiology ofNDs
and several other diseases [55–61].
4.3. Inflammation. Inflammation is part of the complex
physiological response of the body to harmful stimuli or
body injury by internal or external mechanical, chemical,
or immunological agents. This protective mechanism can
however become deleterious when it became excessive or
out of control. In NDs, inflammation may result from
aggregation of misfolded proteins, accumulation of abnor-
mally modified cellular components, response to molecules
released following neuronal injuries, and faulty regulation of
inflammatory control mechanisms [62]. In AD, microglia are
closely associated with neurons expressing A𝛽. On the other
hand, A𝛽 deposits in the brain are thought to be associated
with an inflammatory response leading to increased levels
of proinflammatory cytokines, complement components, and
acute phase proteins [63]. Microglial cells act through a con-
served group of receptors called pattern recognition receptors
(PRRs).These PRRs include Toll-like receptors (TLRs) which
bind conserved molecular motifs displayed by pathogen-
associated molecular patterns (PAMPs) expressed by infec-
tious agents or endogenous danger-associated molecular
patterns (DAMPs) released from damaged tissues. Among
DAMPs that have been identified are A𝛽, 𝛼-synuclein, and
microtubule-associated protein tau. Microglia and astrocytes
can express various TLRs that once bound to their ligands,
can stimulate the production of proinflammatory cytokines
like TNF-𝛼 and IL-6 and chemokine such as IL-8 [64, 65].
As in AD, increased levels of proinflammatory cytokines
are common in the blood, cerebrospinal fluid, and post-
mortem brain tissue of PD [66, 67]. Microglia induce the
release of inflammatory cytokines and lead to activation of
inflammation-mediating enzymes like matrix metallopro-
teinases (MMPs) following activation by 𝛼-synuclein [68,
69]. A component of inflammasomes, nucleotide-binding
domain, and leucine-rich repeat family, pyrin domain con-
taining 3 (NLRP3), is expressed by activated microglia.
Inflammasomes stimulate several inflammatory processes
including thematuration of IL-1𝛽which has been reported to
worsen AD and PD progression in animal models [70]. Non-
steroidal anti-inflammatory drugs have hence been proposed
to have protective effects [71].
Theneuroprotective role ofmicroglia, cytokine, and other
inflammation and immune mechanisms of the CNS are
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also well known [72]. For instance, microglia in the CNS
has a role of clearing apoptotic cells and debris. There is
also an evidence to show that microglia participates in the
elimination of fibrillar A𝛽 through macropinocytosis [73].
However, chronic activation of microglia may lead to loss
of this protective property causing an enhanced production
of various cytokines which impair phagocytosis and other
processes necessary for cell survival [74]. The new concept of
“neuroinflammation” attempts to explain the involvement of
inflammation in the pathology of AD and other NDs using
available studies. However, the controversy as to whether
inflammation is beneficial or detrimental to the CNS of ND
patients is yet to be resolved. Consequently, “a common per-
spective, which implies that, under pathological conditions,
inflammation may exert both detrimental and protective
functions depending on local factors and the timing of
immune activation and shutting-off systems” was proposed
[72].
4.4. Neurotransmitter Level. A number of neurotransmitters
and associated biochemical processes are involved in the
pathology of NDs. These include ACh, DA, and MAO. Low
level of neurotransmitters such as ACh and DA charac-
terized the two major neurodegenerative diseases, AD and
PD, respectively. A loss or downregulation of the neuronal
nicotinic acetylcholine receptors (nAChRs) as well as loss
of the central cholinergic neurons is associated with the
pathogenesis of the AD brain [73].
The MAO catalyzes oxidative deamination of mono-
amines leading to the production of H2O2, aldehyde, ammo-
nia, and amine, all of which have been found to be toxic at
high concentrations and contribute to the pathology of NDs
[74]. Accordingly, MAO-B inhibitors have been reported to
providemild symptomatic effects and to reduce the incidence
of motor fluctuations in PD with fewer side effects. They also
modify the disease state thus making them ideal candidates
for the early treatment of the disease [75].
The DA is a neurotransmitter synthesized by mesen-
cephalic neurons of the substantia nigra and ventral tegmen-
tal area and by hypothalamic neurons of the arcuate and
periventricular nuclei [76]. Proper control of the DA lev-
els and DA receptor interaction is important for normal
functioning of the brain and several neurological and psy-
chiatric disorders results from dysfunctional dopaminergic
system.The dopaminergic pathways are implicated in several
neurological and psychiatric diseases: for example, reduced
levels of DA in PD, degeneration of selected DA neurons
in HD, and dysfunctions of the dopaminergic system in
ischemia and epilepsy [77]. Dopamine has also been shown to
have either neuroprotective or neurotoxic effects in different
physiological and pathological conditions [76, 78, 79].
5. Overview of the Current Pharmacotherapy
There is no cure for NDs and all current therapeutic interven-
tions are aimed at managing the symptoms and improvement
in the quality of life in patients. Therapies for AD, PD, and
other NDs provide symptomatic improvement by several
mechanisms such as restoring the levels of neurotransmitters
or controlling the metabolism of neurotransmitters involved
in the diseases [1, 12, 13, 21]. With the abounding evidences
that the central cholinergic system plays a key role in the
retrieval and storage of memory items in the CNS of mam-
mals [25–27], some current therapeutic strategies are aimed
at boosting the endogenous level of ACh in order to enhance
the cholinergic deficits [80]. Some of these strategies include
the use of muscarinic M2 autoreceptor inhibitors [81] and
nicotinic agonists [82]; ACh releasers or donors [83]; ACh
precursors [84]; and acetylcholinesterase (AChE) inhibitors
which act by inhibiting the hydrolysis of ACh in the synaptic
cleft thereby restoring the levels of the neurotransmitter [85,
86]. Among these strategies, enhancing cholinergic deficit
using agents that can inhibit AChE has been the main focus
of attention by researchers in recent years [27].
Most of the currently available US FDA-approved drugs
for the treatment of cognitive impairment such as donepezil,
tacrine, galanthamine, and rivastigmine elicit their memory
enhancing effectsmainly by inhibitingAChE [12, 87]. In 2003,
memantine was approved for the management of moderate
to severe cases of AD. It is a low affinity and noncompetitive
N-methyl-D-aspartate (NMDA) receptor antagonist able to
counteract neurotoxicity due to excitotoxicity of glutamate,
the major excitatory neurotransmitter in the brain [1], with-
out interfering with the physiological actions of glutamate
necessary for memory and learning [12, 88]. Medications for
PD include levodopa, a precursor of DA; DA receptor agonist
like bromocriptine and ropinirole which can act on the
dopamine receptors in the CNS; and anticholinergic drugs
such as benztropine which acts to give symptomatic relief to
tremors and muscle stiffness [89]. Also, drugs are given to
take care of nonmotor symptoms of the disease. Examples
include nortriptyline for depression related symptoms and
the AChE inhibitors such as donepezil and rivastigmine [90].
6. Classical Examples of Neuroprotective
Drugs of Plant-Origin and
Their Mechanisms of Action(s)
6.1. Polyphenols. Polyphenols are diverse groups of plant
secondary metabolites present in fruits, vegetables, legumes,
cereals, and beverages like tea, coffee, and wine. One of
the most common classes of polyphenols are the C6-C1
structural group of hydroxybenzoic acid derivatives such as
protocatechuic (1) and gallic acid (2) that are derived from
the shikimic acid biosynthesis pathway (Figure 1). The other
diverse group of shikimic acid products of phenolics are the
C6-C3metabolites (phenylpropanoids) such as cinnamic (3),
p-hydroxy cinnamic (4), and caffeic (5) and ferulic (6) acids
which are abundant inmany vegetables, fruits, and seeds (e.g.,
coffee beans).
The other major classes of natural polyphenolic com-
pounds are flavonoids that constitute the C6-C3-C6 struc-
tural configurations (Figure 1). Structurally, they are com-
posed of two six-member aromatic rings designated as A-
and B-rings, joined together by three-carbon chain that may
cyclise to form the third ring-C (7, Figure 1). Biosynthetically,
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Figure 1: Common phenolic compounds. Structures of aromatic acids and the flavonoid skeleton are shown.
the B-ring and linking three-carbon chain (C6-C3) are the
phenylpropanoid skeleton that is derived from the shikimic
acid pathway, while the other C-6 (A-ring) is an acetate
pathway origin that bears the three hydroxyl groups spaced
at meta positions from each other within the benzene ring.
Depending on the position of attachment of the B-ring on
the 3-carbon linking chain (at C-2 of the common flavonoids,
C-3 of the isoflavonoids, and C-4 of the neoflavonoids), or
the chemistry of the linking chain (e.g., presence/absence
of a double bond, cyclisation, presence/absence of a ketone
functional group), flavonoids are further divided into several
classes such as flavones (apigenin, luteolin), flavonols (e.g.,
kaempferol and quercetin), flavanones, isoflavones, antho-
cyanidins, and chalcones. These polyphenolic compounds
can be further esterified with each other or sugars to form
polymeric macromolecules such as tannins. Although phe-
nolic compounds are mainly derived from the shikimic acid
and acetate pathways, other biosynthetic routes such as the
terpenoids and alkaloids can also go through extensive arom-
atization and oxidation reactions to give rise to polyphenolic
compounds.
One of themost important structural features of polyphe-
nols is their potential to treat a diverse range of disease
conditions including NDs and metabolic disorders (e.g.,
diabetes). It is also worth noting that complex diseases such
as the NDs do not have one single pharmacological target
and drugs working through a simple therapeutic principle
(one drug→ one-target→ one disease) may not be effective,
while drugs like polyphenols working through polypharma-
cology (multidrug → multitarget → multidisease/complex
disease) or multifunctional (one drug → multitarget →
multidisease/complex disease) principles have a far better
chance to treat these diseases [91]. It is not surprising then
that even reversing the neurotransmitter deficit in AD and
PD does not offer a cure to NDs. Our decades of research
have shown that polyphenolic compounds directly scavenge
ROS and offer antioxidant effects that are of benefit to
various disease conditions including NDs. The phenolic
structural moiety plays vital role for antioxidant effect with
the catecholic functional group being optimized for such
activity and the gallic acid moiety even far better in inducing
general antioxidant effects [92–103]. While the catechol
structural moiety can also chelate metal ions, flavonoids
especially those with the C-4 keto functional group possess
another site of metal chelation with the 5-OH group, while
those (e.g., flavonols) that bear a free hydroxyl group at
C-3 position have even more pronounced metal chelation
capability through the C-4 keto and C5/C-3 hydroxyl sites.
Far beyond antioxidant effects [92–108], these polyphenols
do also possess numerous other biological activities related to
enzyme inhibition, gene expression, and signal transductions
that attribute to numerous pharmacological effects including
anti-inflammatory effects that play a significant role in NDs.
Good examples of these polyphenols as well as nonphenolic
compounds that have been shown to display neuroprotective
effects are highlighted in the following sections.
6.1.1. Phenolic Acids, Alcohols and Their Derivatives. Acteo-
side (8) and echinacoside (9) are glycosides (Figure 2)
obtained from the dried juicy stem of Cistanche deserticola
or C. tubulosa (Orobanchaceae) as well as many other
plants. They have been shown to have neuroprotective
effects on dopaminergic neurons of substantia nigra in
a chronically intoxicated MPTP (1-methyl-4-phenyl-l,2,3,6-
tetrahydropyridine) mice model of PD [109]. Acteoside
(8) showed neuroprotective effects against the rotenone-
induced damage to SH-SY5Y cells [110] and attenuated
the lipopolysaccharide- (LPS-) induced release of NO in
RAW 264.7 cells through inhibition of NF-𝜅B and activa-
tor protein-1 (AP-1) [111]. Its neuroprotective effects in the
MPTP models of PD revealed that it improved behavioral
deficits in C57BL/6 mice and increased the dopaminer-
gic neurons and content of DA [112]. The neuroprotec-
tive assessment of echinacoside (9) showed that it pre-
vents the 6-hydroxydopamine- (6-OHDA-) induced extra-
cellular loss of monoamine neurotransmitters, such as 3,4-
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid
in rat striatum [113]. In the MPTP-intoxicated mice model,
9 reduced behavioral deficits, cell death, and MPP+-induced
activation of caspase-3 and caspase-8 in cerebellar granule
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neurons as well as increased tyrosine hydroxylase (TH)
expression and the level of striatal DA and its metabolite
[114]. The compound (9) is active orally as an inhibitor of
apoptosis and inducer of neurotrophic factors [115]. There
is no doubt that the active principles of these compounds
(8, 9) are the catechol functional moiety presented in the
3,4-dihydroxyphenyl ethanol and caffeic acid moieties in
their structures. The extended double bond in the caffeic
acid further stabilized the free radical generation/and or
scavenging making it more active as antioxidant and related
pharmacological effects. The neuroprotective effect of caffeic
acid as a free acid and in its ester form such as chlorogenic
acid (11) and caffeic acid phenethyl ester (12) has recently
been reviewed [108]. Besides the common global antioxi-
dant effects through direct scavenging of ROS and metal
chelation, caffeic acid and its derivatives display specific anti-
inflammatory mechanisms in the brain along with inhibition
of key APP processing enzyme, 𝛽-secretase (BACE-1) [116].
Treatment of neuronal cells in vitrowith 11 has been shown to
reverse the A𝛽-induced neurotoxicity [117] while 12 enhances
the expression antioxidant proteins such as HO-1 (heme
oxygenase 1) and the Nrf2 (nuclear factor (erythroid-derived
2)-like 2) in microglia cells both in vitro and in vivo [118]. We
have also shown that gallic acid (2) and related natural prod-
ucts display neuroprotective effects both in vitro and in vivo
under a number of stress conditions [119–122]. In addition
to the above-mentioned plethora of pharmacological effects,
modulation of the human microRNA-17-3p expression has
been shown as the possible mechanism of action for the in
vitro neuroprotective effect of gallic acid derivatives [123].
Hence, compounds bearing the catechol functional groups
such as gallate or caffeic acid have been proposed to offer
benefit in AD and related NDs [108].
Gastrodin (10) is another example of simple derivatives
of the C6-C1 shikimic acid biosynthetic products that may
offer benefit in NDs. It has been obtained from Gastrodia
elata (Orchidaceae) among other plants [124]. Gastrodin
(10) showed neuroprotective effects in the subchronic MPTP
mouse PD model by ameliorating bradykinesia and motor
impairment [125]. It also protected dopaminergic neu-
rons against neurotoxicity through regulating free radicals,
Bax/Bcl-2 mRNA, and caspase-3 and cleaved poly-ADP-
ribose polymerase (PARP) in SH-SY5Y cells stressed with
MPP+ [125].The compound also prevents neuronal apoptosis
by attenuating oxidative stress and inhibits the levels of neu-
rotoxic proinflammatory mediators and cytokines including
iNOS, COX-2, TNF-𝛼, and IL-1𝛽 [126].
6.1.2. Curcuminoids and Resveratrol. The rhizomes of
turmeric (Curcuma longa L., Zingiberaceae) and related
species have long been known for their use as spices
and medicinal properties with their characteristic yellow
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colour attributed to the principal pharmacologically
active principle, curcumin (13, Figure 3). Curcumin can
exist as a diketo (13) or keto-enol form (14) while other
structurally related derivatives isolated from the turmeric
in significant amount include demethoxycurcumin (15)
and bisdemethoxycurcumin (16). The two aromatic phenol
rings which are connected by two sets of 𝛼,𝛽-unsaturated
carbonyl groups are goodMichael acceptor and interact with
a range of biologically reactive species including glutathione
and other nucleophiles, while the aryl methoxyl groups at
the ortho position to the hydroxyl moiety as well as the
conjugated 𝛽-diketone moieties of curcumin are important
structural features for the various pharmacological activities
of these compounds [127]. The range of biological activities
for these compounds collectively, called the curcuminoids,
has been reviewed in the various literature (e.g., [128]) and
numerous synthetic analogues have also been evaluated
in recent years. The presentation herein is thus limited to
highlight that curcumin is one classical example of natural
products that may be employed as a neuroprotective agent
through multifunctional mechanism of actions.
Curcuminoids as well as the crude extracts of C. longa
have been extensively studied for their neuroprotective effects
[129–131]. They prevented MPTP mediated loss of TH-
positive neurons and depletion of DA in inflammation-
mediated neurodegeneration of dopaminergic neurons of
C57BL/6mice in the acuteMPTPmodel.They also mitigated
cytokines, generation of NO, and the expression of protein
inflammatory markers as well as improved motor deficits
produced by the MPTP [129]. Curcumin (13) has also
been shown to have neuroprotective effect in a 6-OHDA-
induced hemiparkinsonian mice model. It decreased the 6-
OHDA-induced loss of striatal TH fibers and nigral TH-
immunoreactive neurons indicating that the neuroprotective
effects may be due to its anti-inflammatory properties, or
direct protection on nigral DA neurons [131]. Curcumin
was also found to ameliorate the A53T 𝛼-synuclein-induced
SH-SY5Y cell death [132] and decrease 𝛼-synuclein-induced
intracellular ROS generation and inhibit caspase-3 activation
in the SH-SY5Y cells [133]. It also protects dopaminergic
neurons from apoptosis in an MPTP mouse model of PD
and ameliorated the loss of dopaminergic axons. It prevents
the degeneration of nigrostriatal neurons by inhibiting the
dysfunction of mitochondria through abolishing the hyper-
phosphorylation of c-Jun N-terminal kinase (JNK) induced
by MPTP [130]. Several studies have reported that curcumin
has antioxidant, anti-inflammatory, and antitumor activity.
In in vitro studies, curcumin inhibited the activities of 𝛽-
secretase, AChE, as well as A𝛽 aggregation, and A𝛽-induced
inflammation. Studies in animal models of AD also indicate a
direct effect of curcumin in decreasing the amyloid pathology
of AD, and oral administration resulted in the inhibition of
A𝛽 deposition, A𝛽 oligomerization, and tau phosphorylation
in the brains of AD animal models and improvements in
behavioral impairment [134–140].
In comparing curcumin and its more stable metabolite,
tetrahydrocurcumin (17, Figure 3), it was observed that the
dienone bridge present in curcumin, but not in TC, is impor-
tant in reducing plaque deposition and protein oxidation in
an AD’s model even though 17 reduced neuroinflammation
and soluble A𝛽, an effect that can be attributed to limiting
JNK-mediated transcription [135]. An alternativemechanism
of curcumin in reducing A𝛽 aggregation or oxidative neuro-
toxicity is through metal chelation. It interacts with copper
and iron thereby offering a net protective effect against A𝛽
toxicity and suppressing inflammatory damage by preventing
the induction of NF-𝜅B [141].
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Resveratrol (18) is a natural stilbene polyphenol found in
red grapes, peanuts, and tea. It is found in the skin of red grape
and can be extracted by fermentation of the skin. It is also
found in high concentration in the oriental plant, Polygonum
cuspidatum (Polygonaceae), used to treat fevers, hyperlipi-
demia, atherosclerosis, and inflammation [142]. Though the
full understanding of its neuroprotective mechanism is yet to
be outlined, in vitro and in vivo studies have shown that 18
can elicit a wide range of beneficial effects on NDs. Among
the several possible mechanisms by which 18 is thought to
act, its antioxidant activity seems to be most important [143].
Given that oxidative stress is implicated in the pathologies
of AD, PD, HD, prion disease, cerebral ischemia, ALS, and
other NDs [55–61], a great deal of emphasis has been given
to study the antioxidant effect of 18 in the respective NDs
models. Furthermore, 18 ameliorates the deleterious effects
triggered by oxidative stress through activation of SIRT1
and vitagenes which can modulate ROS production [144].
Furthermore, it acts by activating SIRT1 and the PGC1𝛼
pathway. Both pathways are known to lead to improved
mitochondrial function and efficiency [143]. Resveratrol also
inhibits A𝛽 formation through sirtuin-dependent activation
as potentiation of the activity of SIRT1 has been noted [144].
The SIRT1 can deacetylate tau protein at multiple residue in
vitro exposing the lysine residue to ubiquitin ligases leading
to themarking of the tau protein for proteosomal degradation
[145]. Allosteric modulation of resveratrol (18) on SIRT1
activates the deacetylation of p53, a protein that induces
indirect phosphorylation of tau which has been reported to
be unregulated in the superior temporal gyrus in AD [146].
Similarly in PD, the antioxidant properties of resveratrol
(18) are believed to play major role in its neuroprotective
effect on dopaminergic neurons [147]. Resveratrol also via
inducing the activation and expression of SIRT1 offers pro-
tection against pathological 𝛼-synuclein aggregation [143].
Another possible mechanism by which 18 can decrease 𝛼-
synuclein protein expression in cellular model of PD is
through the downregulation and partial inhibition of GSK-
3𝛽 (glycogen synthase kinase 3 beta) which has been shown
to protect the dopaminergic neurons from various stress-
induced injuries. Resveratrol (18) can also prevent calcium
elevation caused by repeated and persistent entry of calcium
into the cells as a result of intracellular calcium oscillation
following monoamine induced metabolism of DA and the
production of H2O2 in PD patients [58, 143]. On the basis of
all the available data so far, resveratrol (18) has been widely
reported as a useful natural potential therapeutic agent in
managing NDs [148–154].
6.1.3. Flavonoids. Flavonoids are one of by far the best studied
groups of compounds for their neuroprotective effects and
a selected few are presented here as classical examples of
their representative structural class. Baicalein (19, Figure 4)
belongs to the flavone class of flavonoids that has been
isolated as the principal component of Scutellaria baicalen-
sis (Labiatae). Structurally, this compound has trihydroxy
substitution in the A-ring that mirrors that of the gallate
(2) bioactive structural moiety. The compound has been
evaluated for its neuroprotective effect in the 6-OHDA-
induced cellular and animal models of parkinsonism. It
promoted neurite outgrowth in PC12 cells and attenuated
the 6-OHDA-induced cell apoptosis in the SH-SY5Y cells.
It also attenuated muscle tremor in 6-OHDA-lesioned rats
and mitigated against astroglial response and increased TH-
positive neurons in substantia nigra [155]. The effect of
baicalein (19) on rotenone-induced neurotoxicity in PC12
cells was also evaluated. It inhibits the accumulation of
ROS, suppressed rotenone-induced apoptosis and produc-
tion of ROS, promotes mitochondrial active respiration,
and prevents the rotenone-induced deficiency of ATP and
swelling of isolated brain mitochondria [156]. Baicalein (19)
also protects the SH-SY5Y cells from 𝛼-synuclein oligomer-
induced toxicity [157] and against the MPTP-induced fall
of TH-positive neurons in the substantia nigra as well as
preventing an MPTP-induced decrease in DA levels [158].
It has also been shown to improve impaired spontaneous
motor activity and rotarod performance induced byMPTP in
C57BL/6mice [158];modulate the balance between glutamate
and gamma amino butyric acid [159]; increase the counts
of dopaminergic neurons [103]; and enhance the levels of
DA and 5-hydroxytryptamine in the striatum [158]. Baicalein
(19) also inhibits the following: cytochrome oxidase subunit
I (CO-I) mRNA expression in the subthalamic nucleus
[115], the oxidative stress and the astroglial response [160],
the oligomerization of 𝛼-synuclein in cell-free and cellular
systems, 𝛼-synuclein fibrillation in cell-free systems, and
the formation of 𝛼-synuclein oligomers in HeLa and SH-
SY5Y cells [157]. On the other hand, the ethanolic extract
of S. baicalensis was shown to decrease the LPS-induced
expression of inducible nitric oxide synthase (iNOS), NO,
cyclooxygenase-2 (COX-2), and prostaglandin E2 levels in
BV-2 and RAW264.7 cells [160]. The neuroprotective effect
of 19 through antioxidant and mitochondrial mechanisms hs
also been reviewed [161].
Flavonoids have also generally been implicated in the
management of AD [162–164]. Hence, baicalein (19) has
been reported to prevent A𝛽-induced impairments in hip-
pocampal LTP through activation of Akt phosphorylation
and memory deficits in AD model. It also inhibits 12/15-
lipoxygenases and GSK3𝛽 activity, reduces BACE1 and A𝛽
production, prevents tau phosphorylation, and restores spine
density and LTP in AD model [165, 166]. In addition to
inhibiting A𝛽-induced depolarization, 19 also functions as
an antagonist of AMPA (𝛼-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid) and NMDA receptors and improves
neurocognition [167, 168]. It also attenuates neurological
deficits and preserves blood-brain barrier integrity in a
rat model of intracerebral hemorrhage and inhibits AChE
[169–172]. Recently, cocrystals of baicalein with isoniazid,
isonicotinamide, caffeine, and theophylline were developed
with BaiCaf having superior powder dissolution and pharma-
cokinetic behaviors [173].
Pinocembrin (20) is a flavonoid (favanone subclass)
isolated from several plants including the Pinus heartwood,
Eucalyptus, Populus, Euphorbia, and Sparattosperma leucan-
thum [174].The neuroprotective effects of 20 against cerebral
ischemic injury have been reported with a wide therapeutic
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Figure 4: Examples of flavonoids with neuroprotective effects.
window that has been shown to be attributed to its antiex-
citotoxic effects [175]. It has been shown that 20 alleviates
cerebral ischemic injury induced by occlusion of the middle
cerebral artery in rats [176, 177] as well as enhanced cognition
by protecting cerebral mitochondria structure and function
against chronic cerebral hypoperfusion in rats [178]. Other
mechanisms of action include increasing ADP : oxygen ratio,
glutathione, state 3 respiration state, neuronal survival rates,
and oxidative phosphorylation rate in NADH/FADH2 and
decreasing LDH release, ROS, NO, neuronal NOS (nNOS),
iNOS, and 4 respiration state (V4) in NADH [177]. It also
enhances ATP content in brain mitochondria in the SH-
SY5Y cells [175, 179]. Furthermore, it decreased brain edema,
improved cerebral blood flow, and increased the viability
and mitochondrial membrane potential of cultured rat cere-
bral microvascular endothelial cells [180]. Pinocembrin (20)
also possesses anti-inflammatory [181, 182] and antioxidant
activities [183, 184]. Pinocembrin improves cognition and
protects the neurovascular unit in Alzheimer-related deficits
and inhibits A𝛽-induced neurotoxicity through Nrf2/HO-1
pathway in the SH-SY5Y cells [185–187].
The consumption of tea has been shown to be inversely
correlated with the incidence of dementia, AD, and PD
due primarily to its main catechin polyphenol constituent
(−)-epigallocatechin-3-O-gallate (21) among others.The (−)-
epigallocatechin-3-O-gallate (21) has been reported to show
neuroprotective effects inmany cellular and animalmodels of
neurological disorders. In addition to the known antioxidant
activity of catechins, the modulation of signal transduction
pathways, cell survival/death genes, and mitochondrial func-
tion all contribute significantly to the induction of neuron
viability [188]. Recent studies have linked the biological
activities of catechins to their ability to modulate vari-
ous protein kinase signaling pathways in addition to their
antioxidant/radical-scavenging potential [188, 189]. Hence, 21
has been shown to improve cognitive decline associated with
age as well as protect against cerebral ischemia/reperfusion
injuries [190] and brain inflammation and neuronal dam-
age in experimental autoimmune encephalomyelitis [191]. It
also prevented striatal DA depletion and substantia nigra
dopaminergic neuron loss in the MPTP PD model [192].
It reduces cerebral amyloidosis in AD’s transgenic mice
[193] and prevented neuronal cell death due to 6-OHDA,
1-methyl-4-phenylpyridinium and A𝛽 [194, 195]. It boosts
cellular protein stability and prevents cell damage and cell
death by modulating macroautophagy [196]. Other complex
mechanisms of action that may explain its beneficial neuro-
protective effects have also been reported [197].
The flavonol glycoside, rutin (22), its aglycone quercetin,
and a related glycoside isoquercetin (quercetin 3-O-
glucoside) have been shown to possess neuroprotective
effects on glutamate-induced oxidative injury in the
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HT22 hippocampal cells [198, 199]. Rutin (22) reportedly
reduces the levels of ROS, MDA, NLRP3 (NLR family
pyrin domain containing 3), ASC (apoptosis-associated
speck-like protein containing a CARD), caspase-1, IL-1𝛽,
and IL-18 and attenuates histologic alteration as well as
improving locomotion recovery [200]. Quercetin also
dose-dependently reduced the A𝛽- (A𝛽(1–42)-) induced
paralysis in Caenorhabditis elegans by decreasing the
amount of aggregated proteins [201] and antagonized
the high glucose-induced damage of Schwann cells by
inducing autophagy [202]. Rutin (22) attenuates the
isoflurane-induced neuroapoptosis by modulating JNK (c-
June-N-terminal kinase) and p38 MAPK (mitogen-activated
protein kinase) pathways in the hippocampi of neonatal rats
[203]. It also protects against neuronal damage in vitro and
ameliorates doxorubicin-induced memory deficits in vivo
in Wistar rats [204]. Rutin (22) has also shown to inhibit
protein aggregate formation, depolymerize aggregates, and
reduce neurotoxicity [205]. Details of the mechanism of
action of rutin and related compounds have been outlined in
our previous review communication [199].
Puerarin (23) is an example of the isoflavonoid subclass of
flavonoid compounds that has been obtained from Pueraria
lobata (Leguminosae) [206, 207]. It has been observed to
upregulate the phosphorylation of Akt in MPP+-induced
cytotoxicity in SH-SY5Y cells and inhibits MPP+-induced
nuclear translocation of p53, expression of Bax, and caspase-
3-dependent programmed cell death [208]. Puerarin (22) was
also reported to prevent the dysfunction of the proteasomal
system thus preventing the accumulation of conjugated
proteins [209]. It was shown to suppress the LPS-induced
release of iNOS and phosphorylation of MAPKs in N9
cells [210] and inhibits the MPP+-induced phosphorylation
of JNK [211]. In 6-OHDA-lesioned rats, 23 significantly
increased the protein expression of DJ-1 and SOD-2 in
the substantia nigra [212] and increased the expression of
the glial cell-derived neurotrophic factor in the striatum of
rats administered with 6-OHDA [213]. Other studies have
also shown the neuroprotective effects of 23 in AD [214,
215]. Puerarin also suppresses the A𝛽(1–42)-induced primary
cortical neuron death [216] thus protecting against A𝛽(1–42)-
induced learning and memory impairments in mice [217].
It also attenuates myocardial hypoxia/reoxygenation injury
by inhibiting autophagy via the Akt signaling pathway and
inhibits oxidative stress in STZ-induced SADmice [218, 219].
Overall, numerous reports from our laboratories and others
have shown the neuroprotective effects of various classes
of flavonoids (e.g., [220, 221]). Extensive literature review
articles in the field are also available [220–226].
6.1.4. Other Phenolic Compounds. Numerous phenolic com-
pounds that are not of the acetate/shikimate pathway ori-
gin but with promising neuroprotective effects have been
reported [227]. Of significance are the diterpenoids Ros-
marinus officinalis (24–29, Figure 5) which have significant
antioxidant, anti-inflammatory, antiamyloid, and anti-AChE
activities [228]. Carnosic acid (24) from R. officinalis was
reported to have neuroprotective effects on cyanide-induced
brain damage in cultured rodent [229] while the protec-
tive effects of carnosol (28) in vitro on rotenone-induced
neurotoxicity in cultured dopaminergic cells have also been
reported [230]. The antioxidant potential of carnosic acid
(24) and carnosol (28) has been well documented and their
detailed neuroprotective mechanism have been reviewed
recently [228]. For example, carnosic acid protects neuronal
cells from ischemic injury by scavenging ROS [231] while
carnosol inhibits the CU2+-induced LDL oxidation [232] and
chelate Fe2+ [233]. On inflammation, carnosol (28) inhibits
the adhesion of TNF-𝛼-activated monocytes to endothelial
cells and suppresses the expression of intercellular adhesion
molecule at the transcriptional level [234]. It also inhibits
the TNF-𝛼-induced signaling pathways through inhibitor of
NF𝜅-B (IKK-𝛽) activity as well as the upregulation of HO-
1 expression [235]. Both carnosic acid (24) and carnosol
(28) antagonized intracellular Ca2+ mobilization induced
by a chemotactic stimulus, coupled with inhibition of ROS
generation [236]. Carnosic acid (24) also suppressed A𝛽42
secretion [237, 238] and inhibited AChE [239, 240] and its
therapeutic potential for AD both in vitro and in vivo is well
documented [241, 242].
6.2. Alkaloids. Galantamine (30, Figure 6) is an alkaloid
originally isolated from Galanthus woronowii (Amarylli-
daceae) and related species including G. caucasicus as well as
from the related genera like Narcissus, Leucojum (Leucojum
aestivum), and Lycoris (Lycoris radiate) [243]; but now it
can also be obtained synthetically. With the trademark of
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Razadyne or Nivalin, galantamine (30) is an approved drug
for the treatment of mild to moderate dementia in AD.
Much work on its identification and properties was done
by Mashkovsky and Kruglikova-Lvova in the 1950s. Before
the FDA approval for its use for the management of AD in
the US, the compound has been used for decades in Eastern
Europe and Russia for various indications such as treatment
of poliomyelitis, myasthenia, andmyopathy. It had also found
clinical use as anesthetics to reverse neuromuscular paralysis
by tubocurarine-like muscle relaxants [244]. Galantamine
(30) acts as a selective, competitive, and reversible inhibitor
of AChE with very little butyrylcholinesterase (BuChE)
inhibitory activity [244]. The selectivity is in the range of
10–50-fold for AChE than for BuChE [245]. As a competitive
inhibitor, it competes with ACh at the AChE binding site,
and since this is dependent on ACh concentration, it may
be less likely to bind to the enzymatic site in areas with
high ACh concentration [246]. It is also proposed to be an
allosteric ligand at nAChR thereby inducing its modulatory
effect leading to enhanced effect of ACh and cholinergic
transmission [86]. The neuromodulatory activity at nicotinic
receptors in addition to its effect on cholinergic transmission
affects other neurotransmitter systems such as monoamines,
glutamate, and 𝛾-aminobutyric acid (GABA). These effects
may improve cognitive dysfunction and psychiatric illness
in schizophrenia, major depression, bipolar disorder, and
alcohol abuse [247]. Galanthamine (30) showed protective
effects on NO-mediated glutamate neurotoxicity when tested
on primary cultures from the cerebral cortex of fetal rats.
It also prevented the glutamate- and ionomycin-induced
neurotoxicity [248]. The neuroprotective effect against both
acute and moderate glutamate treatments was mediated
through nAChRs 𝛼4- and 𝛼7 and phosphatidylinositol 3-
kinase-Akt pathway [249, 250]. Galanthamine appears less
tolerated when compared to other approved drugs but better
toleration was noted when gradually titrated over more than
three months [86].
Rivastigmine (trade nameExelon, 31) is another approved
drug of natural origin for the treatment of AD. It is a
semisynthetic derivative of physostigmine (32) obtained
from Physostigma venenosum (Fabaceae). Also called Cal-
abar bean, P. venenosum was used for ordeal poisoning by
locals in the 19th century [251]. Rivastigmine, a powerful
carbamate inhibitor, inhibits both BuChE and AChE by
covalently binding to the esteratic part of the active site of
the AChE in a slow-reversible manner. In addition to AD,
rivastigmine is also indicated for the management of Lewy
body dementia and PD dementia [252]. Rivastigmine (31)
which was initially formulated in tablet form is now available
as transdermal drug delivery systems (drug “patches”) which
has the advantage of providing controlled and continuous
delivery of drugs through the skin,minimizing the processing
of the drug in the liver, stomach, and intestines as well as
improving compliance [85]. It is also able to reduce the side
effects associated with the use of the drug [86].
Berberine (33) is an isoquinoline alkaloid of the proto-
berberine type isolated from numerous plants with multiple
therapeutic implications. It shows neuroprotective effect in
various animal models of CNS-related disorders [253, 254].
Berberine (33) has D2 dopamine receptor antagonist and
D1 dopamine receptor agonist effects [255]. It reverses the
A𝛽(1–40)-induced memory [256], reduces A𝛽-production by
modulating APP processing in human neuroglioma H4 cells
[257], and inhibits AChE [258, 259]. It also reversed the
NMDA-induced excitotoxicity [260] and reduced D1 DA
and NMDA receptor bindings in the cortex [261]. Given
that berberine (33) is a multifunctional compound with
broad range of pharmacological effects ranging from anti-
inflammatory and antioxidant to neuroprotection in a variety
of models [262], it has been the subject of intense medicinal
chemistry researches that aim to synthesize a better novel lead
derivative compound [263]. The rather simple compound,
indole-3-propionic acid (34) that can be obtained by deam-
ination of the amino acid tryptophan, is a further example
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Figure 7: Structures of ginsenosides and tenuigenin.
of neuroprotective natural products that can be obtained
through a simple biosynthetic route [264]. Compound 34,
isolated from Clostridium sporogenes (Gram-positive bacte-
ria), has been reported as a potent antioxidant that attenuates
neuronal damage and oxidative stress in the CNS [265]. It has
also been detected in the plasma and cerebrospinal fluid of
humans [266] where it offers complete protection to primary
neurons and neuroblastoma cells against oxidative damage
and death caused by exposure to A𝛽 [267]. This suggests
that 34 may form part of the body’s natural defense against
neuronal injuries due to free radicals [267] which is the
basis for the development of some probiotic drugs such as
OXIGON for the management of NDs.
6.3. Terpenoids
6.3.1. Triterpenoids. Ginsenosides (35–41, Figure 7) are good
examples of neuroprotective triterpenoids obtained from
the roots and rhizomes of P. ginseng and P. notoginseng
(Araliaceae) [268].The aqueous extract of P. ginseng has been
evaluated for its neuroprotective effects against the MPP+-
induced cytotoxicity in SH-SY5Y human neuroblastoma
cells [129]. It was observed that the extract reduced the
overproduction of reactive ROS, release of cytochrome c,
and activation of caspase-3 and elevated Bax/Bcl-2 ratio,
thereby increasing the cell survival. Ginsenoside Rg1 (41) was
reported to decrease the cytotoxicity induced by H2O2 in
PC12 cells thus explaining its antioxidant activity. It also pro-
tects cells from injury induced by H2O2 by downregulating
the ERK1/2 (extracellular signal-regulated kinases 1/2) as well
as decreasing the activation of the NF-𝜅B signaling pathway
[269]. Other studies showed that ginsenoside Rg1 (41) renews
an iron-induced reduction in mitochondrial transmembrane
potential, inhibits the 6-OHDA-induced upregulation of an
iron importer protein divalent metal transporter 1 with iron
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responsive element (DMT1-IRE), inhibits iron regulatory
proteins, thereby downregulating the DMT1-IRE expression
[270], inhibits the MPP+-induced upregulation of DMT1-
IRE [271], attenuates the MPTP-induced elevated iron levels,
decreases the expression ofDMT1, and increased ferroportin-
1 expression [272].
Ginsenoside Rg1 (41) was found to have a neuroprotec-
tive effect in dopaminergic neurons through IGF1 receptor
signaling pathway in a 6-OHDA-induced nigrostriatal injury
model of PD [273]. It also has protective effects on dopamin-
ergic neurons in ovariectomized female SD rats injected
intracerebroventricularlywith 6-OHDA [274]. Compound41
also has anti-inflammatory effect: it inhibits proinflammatory
markers such as iNOS, NO, and TNF-𝛼 and expression
of ionized calcium binding adaptor molecule 1 in both
the cerebral cortex and hippocampus of mice as well as
suppressing effect on the downstream inflammatory markers
[275]. Saponins obtained from P. notoginseng also showed
potent neuroprotective effect on MPP+-induced toxicity to
PC12 cells and Kunming mice [276, 277].
Ginsenoside-Rg1 (41) has neuroprotective effect on cere-
bral ischemia/reperfusion injury in rats by downregulating
protease-activated receptor-1 expression [278]. It can reduce
neuronal death induced by hypoxic–ischemic insults, an
effect probably mediated by the activation of glucocorticoid
receptors, and by the inhibition of calcium influx through
NMDA receptors and L-type voltage-dependent Ca2+ chan-
nels and the resultant reduction of intracellular free Ca2+
[279]. It also enhances neurite outgrowth and protects against
neurotoxicity induced by A𝛽 through amechanism involving
Akt and ERK 1/2 signaling [280]. This compound (41) is
also shown to be capable of helping Schwann cells recover
from the oxidative insult induced by H2O2. It upregulates
the level of SOD, GSH, and CAT and decreased the level
of MDA in Schwann cells treated with H2O2 both in vitro
and in vivo (sciatic crush injury model in rats). It has also
shown to inhibit the proapoptotic effect of H2O2, as well
as the detrimental effect of H2O2 on cell number and cell
viability. Furthermore, it increases the mRNA levels, protein
levels, and secretion of nerve growth factor and brain-derived
neurotrophic factor in Schwann cells after incubation with
H2O2 [281]. Ginsenoside Rg1 (41) as well as 38 and others
have been shown to reduce the amount of A𝛽 detected in the
brains of animals after single oral doses [280]. Review articles
on the effects of ginseng extracts and isolated ginsenosides
along with the aglycones relevant to cognition in humans are
also available [282, 283].
Tenuigenin (42) obtained from the dried root of Poly-
gala tenuifolia (Polygalaceae) [284] is another example of
a triterpenoid neuroprotective agent. Evaluation in the 6-
OHDA-induced cytotoxicity in SH-SY5Y cells showed that
tenuigenin (42) increased cell viability and reduced cell
death [284]. It also protects against the 6-OHDA-induced
damage of the mitochondrial membrane and increased glu-
tathione and SOD expression [284]. It has also been shown
to downregulate the caspase-3 activity at the translational
level and upregulate the expression of TH in 6-OHDA thus
indicating neuroprotective effects on dopaminergic neurons
through antiapoptotic and antioxidant mechanisms [284].
It also showed neuroprotective effect on neuroinflammation
induced by the LPS in adult male SD rat by significantly
improving the level of DA in the striatum and preventing the
LPS-induced upregulation of cytokines [285].
Tenuigenin (42) exerts an anti-inflammatory effect by
downregulating the release of NO, MMP-9, and cytokines.
It can decrease the release of NO from the LPS-activated rat
microglia in a dose-dependent manner and directly scavenge
the NO radical. It has also been shown to decrease the
secretion and mRNA levels of MMP-9 and proinflammatory
cytokines (TNF-𝛼/IL-1𝛽) in activated microglia as well as
inhibit the secretion of MMP-2 [286]. It has also been
reported that tenuigenin (42) inhibits the LPS-induced TNF-
𝛼, IL-1𝛽, IL-6, and PGE2 production while the expression
of Nrf2 and HO-1 was shown to be upregulated in a dose-
dependent manner. In in vivo studies, it relieved the LPS-
induced memory deficit in the Morris water maze and
passive avoidance tests. This suggests the anti-inflammatory
mechanism of neuroprotection through activation of the
Nrf2-mediated HO-1 signaling pathway [287].
6.3.2. Diterpenoids. In addition to the polyphenolic diter-
penoids of Rosemary that have already been discussed
in the preceding sections, several other diterpenes have
been shown promising effect as neuroprotective agents.
Ginkgolides (43–49, Figure 8) are a group of diterpenoids
isolated from Ginkgo biloba (Ginkgoaceae), an ancient Chi-
nese tree known for its health prompting effects. There have
been several reports on the neuroprotective properties of
G. biloba [288–290]. Hence, the extract of G. biloba has
been reported to offer neuroprotection in theMPTP-induced
nigrostriatal dopaminergic toxicity in C57 mice [291]. The
various ginkgolides isolated from the plant have also been
linked with neuroprotection. Ginkgolides protect PC12 cells
against hypoxia-induced injury by p42/p44 MAPK pathway-
dependent upregulation of HIF-1𝛼 (hypoxia-inducible factor
1𝛼) expression and HIF-1-DNA binding activity [292]. The
neuroprotective effect of ginkgolide K (50), for example,
on glutamate-induced cytotoxicity in PC12 cells has been
demonstrated and shown to be mediated through inhibition
of ROS generation and Ca2+ influx [293]. Ginkgolide K
(50) has also shown to reduce the volume of infarction
and brain water content and improve neurological deficit
score in ischemia-reperfusion-induced cerebral injury. It also
reversed the level of MDA, NO, NOS, and SOD. Neuronal
injurywas also significantly improved following pretreatment
with ginkgolide K (50) [294]. Ginkgolide B (44) and bilob-
alide (51) have also shown to exert neuroprotection under
normoglycemia, while ginkgolide B (44) reduces ROS species
and MDA levels in both normoglycemia and hyperglycemia
ischemic rats [295]. Bilobalide (51) has also been previously
reported with multiple mechanisms of action for its neu-
roprotection effect, including preservation of mitochondrial
ATP synthesis, inhibition of apoptotic damage induced by
staurosporine or by serum-free medium, suppression of
hypoxia-induced membrane deterioration in the brain, and
actions of increasing the expression of the mitochondrial
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DNA-encoded COX III subunit of cytochrome c oxidase and
the NADH dehydrogenase subunit 1 [296]. Ginkgolide B
(44) also inhibits the 6-OHDA-induced apoptosis of PC12 by
upregulating the calbindin D28K mRNA and by decreasing
the intracellular calcium concentration [297] and protects
against ischemic stroke [298]. Ginkgolide B (44) has also
been reported to attenuate the A𝛽(1–42)-induced oxidative
damage and altered cellular responses in human neuroblas-
toma (SH-SY5Y) cells [299].
6.3.3. Sesquiterpenes. Three cadinane sesquiterpenes, com-
miterpenes A–C (52–54, Figure 9) isolated from the
resinous exudates of Commiphora myrrha (Burseraceae),
were reported to show neuroprotective effects against the
MPP+-induced neuronal cell death in SH-SY5Y cells [300].
Also, tricyclic sesquiterpene 𝛼-copaene (55) prevents the
H2O2-induced neurotoxicity [301]. Shizukaol B (56) is a
lindenane-type dimeric sesquiterpene isolated from Chlo-
ranthus henryi (Chloranthaceae). It has anti-inflammatory
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effects in the LPS-activated microglia partly by modulating
JNK-AP-1 signaling pathway. Shizukaol B (56) has been
shown to suppress the expression of iNOS and COX-2 and
production of NO, TNF-𝛼, and IL-1𝛽 in LPS-stimulated
BV2 microglia. It also inhibits the LPS-mediated JNK 1/2
activation and significantly blocks the LPS-induced AP-1
activation [302]. Many other structurally related dimeric
sesquiterpenes (e.g., chloramultilide A and spicachlorantin
B) along with others including zederone epoxide (57)
have been isolated from C. henryi with antineuroinflam-
matory effects. They showed significant antineuroinflam-
matory effects by inhibiting NO production in the LPS-
stimulated murine BV-2 microglial cells with relatively low
cytotoxicity [303]. Atractylenolide-I (58) is isolated from
the rhizomes of Atractylodes macrocephala (Asteraceae) a
common medicinal plant in Chinese traditional medicine.
The compound has been reported to reverse the MPTP-
induced behavioral deficits, decreased microglial activation,
and conferred protection to dopaminergic neurons in the
mousemodel of PD [304]. A number of other sesquiterpenes’
neuroprotection [305] prevents A𝛽(25–35)-induced toxicity in
mouse cortical neurons and scopolamine-induced cognitive
impairment in mice [306].
6.3.4. Monoterpenes. Paeoniflorin (59, Figure 10) obtained
from Paeoniae alba Radix (Paeoniaceae) [307] has been
shown to protect striatal nerve fibers and TH-positive
neurons in SN; mitigate bradykinesia observed in MPTP
model of PD; and ameliorate dopaminergic neurodegenera-
tion [308]. The neuroprotective and antineuroinflammatory
effects of paeoniflorin (59) can also be linked with the activa-
tion of adenosine A1 receptor [308]. In the 6-OHDA-induced
unilateral striatal lesion in rats, it reduced apomorphine-
induced rotation [309]. It also protected PC12 cells from
MPP+ and acid-induced damage; reduced the influx of Ca2+
and its cytosolic content; upregulatedmicrotubule-associated
protein 1A/1B-light chain 3-phosphatidylethanolamine con-
jugate protein, and inhibited the MPP+-induced overexpres-
sion of lysosome-associated membrane protein 2a [310].
7. General Summary and Conclusions
A number of people living in developing countries rely on
herbal medicines not only because they are considered safe
but the costs associated with modern medicines are beyond
the reach ofmany people.The growing prevalence of complex
metabolic and neurodegenerative diseases in the western
societies that have no drugs of cure also means that plant
medicines could still be exploited as a valuable source of
lead compounds as has been done throughout the history of
mankind. The various biologically active secondary metabo-
lites belonging to the polyphenols, primarily the shikimic
acid and/or acetate pathways origin along with other biosyn-
thetic pathways, and other classes of compounds including
the alkaloids and terpenoids have been documented from
numerous genera of plants. In this communication, these
classes of compounds have been systematically presented
to give an overview of plant-derived neuroprotective agents
acting through diverse mechanisms of action(s). We have
provided an account of some neurodegenerative diseases,
some important factors in their pathogenesis, and exemplary
neuroprotective drugs isolated from medicinal plants that
have been used in different traditional systems of medicine.
The interlinking mechanisms of oxidative stress and
inflammation in neurodegenerative diseases have been
shown to play key role in processes leading to neuronal cell
death. Perhaps the most important feature of the selected
natural products in this communication is their multifunc-
tional nature that seems to give the compounds significant
potency through antioxidant and anti-inflammatory mecha-
nisms among others. Associated with these mechanisms are
the other linking pathological hallmarks of NDs where pro-
tein precipitation/aggregation play pivotal role in inducing
the oxidative stress and unregulated inflammation that are
associated with neuronal deletions in specific areas of the
brain. The overall common mechanisms of action for plant-
derived neuroprotective agents are depicted in Figure 11.
On the basis of the plethora of evidences presented for the
plant-derived neuroprotective agents, further research on
details of efficacy studies especially on human subjects is well
warranted.
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